October 22, 2009
The largest segment of the market, prescription gastrointestinal drugs, is expected to be worth more than $26 billion in 2009, and to increase to nearly $27 billion in 2014, for a 5-year CAGR of 0.5%.
The other segment of the market, over-the-counter gastrointestinal drugs, is estimated to be worth $4.8 billion in 2009. By 2014, that is expected to grow at a CAGR of 1.7% to reach $5.2 billion.
The gastrointestinal drug market is rapidly growing due to recent advancements in pharmaceutical products, advancements in drug delivery of medications and accurate diagnosis. Emphasis has been placed on early detection and treatment of disorders.
GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014
Source: BCC Research
This report is designed to be a comprehensive business tool to provide an in-depth look at gastrointestinal disorders. It provides an overview of the gastrointestinal system; gives a brief explanation of disorders of the gastrointestinal system; cites risk factors, where applicable; cites incidence and mortality; presents current pharmaceutical treatments, market size and market participants in both prescription and over-the-counter arenas; and presents potential treatments in research and development, potential market size and market participants.
Aside from the two general segments, prescription and over-the-counter gastrointestinal pharmaceuticals, the market is further broken down into the drugs to treat specific disorders within the gastrointestinal system including:
- Gastrointestinal tract disorders
- Gastrointestinal tract wall disorders
- Gastrointestinal motility disorders
- Gastrointestinal malabsorption disorders
- Gastrointestinal cancers.
Each subsegment is addressed in detail, describing disorders and the diseases, identifying current and potential products on the market, and competitors involved in the market.
Gastrointestinal Pharmaceuticals: Technologies and Markets( PHM046B )
Publish Date: September 2009
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: firstname.lastname@example.org as the source and publisher. Thank you.